Effect of Taurine on Glycemic, Lipid and Inflammatory Profile in Individuals With Type 2 Diabetes

• Status: Not yet recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Type 2 diabetes mellitus (DM2) is characterized by chronic hyperglycemia, which is a risk factor for comorbidities and death. Although conventional pharmacotherapy is effective, some individuals do not reach the glycemic targets, requiring adjuvant therapies. Taurine is a semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a nutritional supplement. Pre-clinical studies show its effectiveness in reducing blood glucose and cholesterol, but there are no well-conducted clinical studies evaluating the effect of taurine on glycated hemoglobin. Additionally, animal models showed that taurine had a protective effect from diabetic nephropathy. The hypothesize of this study is that taurine administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in DM2 individuals.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital de Clinicas de Porto Alegre

Criteria

Inclusion criteria

• Female and male individuals, with clinical diagnosis of DM2 for at least 6 months;

• Age over 30 years;

• BMC equal to or above 18.5 kg/m2, without weight change in the last 3 months;

• HbA1c between 7.5% and 10.5%.

Exclusion criteria

• Use of herbal supplements, antioxidants, and multivitamins in the last 3 months;

• Pregnancy or lactation;

• Chronic renal failure with glomerular filtration rate calculated by MDRD < 30 mL/h;

• Myocardial infarction in the last than 6 months

• Current neoplasia;

• Chronic use of glucocorticoids;

• Bariatric surgery.